| Assessment Status | Rapid Review Complete |
| HTA ID | 25012 |
| Drug | Ravulizumab |
| Brand | Ultomiris® |
| Indication | Ravulizumab (Ultomiris®) is indicated as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis who are anti-acetylcholine receptor antibody-positive. |
| Assessment Process | |
| Rapid review commissioned | 17/02/2025 |
| Rapid review completed | 12/03/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ravulizumab compared with the current standard of care. |
